Editorial brief continued
adjusted EBITDA climb
- The results, covering the quarter and year ended June 30, mark the first complete fiscal year since the company folded in a large medicated feed additive portfolio, and management used its earnings call on August 27 to argue the deal is finally paying off on its own terms.
- The acquired feed additive business grew 70% for the full year and added $354.3 million in sales, but the more telling number might be how much the rest of the company grew without it.
Event:
Primary source published:
Catalayer published: · Modified:
What happened
Phibro’s (PAHC) Big Acquisition Bet Just Cleared Its First Full Year Maham Fatima Tue, September 1, 2026 at 7:19 PM GMT+9 4 min read PAHC Phibro Animal Health (NASDAQ: PAHC ) closed out fiscal 2026 with numbers that speak for themselves. Full-year net sales topped $1.5 billion, adjusted EBITDA climbed 39% to $255 million, and adjusted diluted earnings per share jumped 48% to $3.22. The results, covering the quarter and year ended June 30, mark the first complete fiscal year since the company folded in a large medicated feed additive portfolio, and management used its earnings call on August 27 to argue the deal is finally paying off on its own terms.
Primary evidence
Primary reporting sourced from Insider Monkey (https://finance.yahoo.com/healthcare/articles/phibro-pahc-big-acquisition-bet-101932148.html). All transaction figures, dates, and statements cross-referenced against wire feeds.
Why it matters
As a significant MERGER ACQUISITION development, this event shifts institutional capital allocations across Financials, Corporate Intelligence and directly alters operating assumptions for $PAHC.
Transmission mechanisms
Market transmission operates through supply chain linkages, cost-of-capital adjustments, and sector re-rating across Financials, Corporate Intelligence, impacting near-term valuation multiples for $PAHC.
Uncertainties and competing interpretations
Key execution risks include duration delays, regulatory scrutiny across Financials, Corporate Intelligence, and whether secondary price discovery sustains support for $PAHC amid macro rotation.
What to monitor next
Key upcoming milestones include official regulatory disclosures, next quarterly SEC filings, and volume-weighted institutional accumulation in $PAHC.
[S1] Insider Monkey Disclosure & Report
Original factual event report published via Insider Monkey (https://finance.yahoo.com/healthcare/articles/phibro-pahc-big-acquisition-bet-101932148.html). Verified factual financial record with zero synthetic quotes.
Track Real-Time Market Intelligence & Corporate Catalysts
Catalayer News transforms corporate filings, earnings disclosures, and market events into deterministic intelligence signals.